Written by Henry Smith · Reviewed by Smiths Insurance & KiwiSaver — licensed Financial Advice Provider (FSP712931) · Last updated 2026-09-17

Insurance After Prostate Cancer in NZ: PSA Monitoring and Cover

A prostate cancer diagnosis in New Zealand does not automatically end your ability to get insurance; the outcome depends heavily on whether you are on active surveillance or have been treated. Active surveillance manages a low-risk, localised tumour, Gleason 3+3=6, PSA under 10, with three-monthly PSA tests rather than surgery, while treated prostate cancer usually means a prostatectomy, radiotherapy or chemotherapy. Insurers assess life, trauma, health and income protection cover differently for each, and the same active-surveillance diagnosis can mean a full trauma payout from one insurer and nothing from another. A licensed adviser can present a specific Gleason score, PSA history and treatment path to the insurers most likely to offer useful terms.

In short

Prostate cancer is NZ's most common cancer in men, with around 4,000 new cases and 700 deaths a year (Te Aho o Te Kahu, read 17 September 2026).
A Gleason 3+3=6, PSA-under-10, T1 tumour, the active-surveillance entry profile, is a full trauma payout under one insurer and excluded entirely under another's (Fidelity Life, 30 April 2025; Pinnacle Life).
About 19% of adult NZ men had a PSA test each year from 2015 to 2019, rising to 47% at ages 70 to 79 (bpac.org.nz, 7 July 2020).
Monthly life cover of $500,000 at age 55 runs from about $170 to $190, indicative standard rates across four insurers' rate cards as at 8 September 2026 (Fidelity Life).

NZ's PSA and referral guidance draws a clear line between cancer low-risk enough to watch and cancer that needs treating, a line that matters as much to an underwriter as a urologist.

A man sits across a desk from his doctor, an anatomical prostate diagram and a small blood-sample vial resting on the desk between them

What does a prostate cancer diagnosis in NZ involve, and how common is it?

A prostate cancer diagnosis starts with a raised PSA blood test, usually followed by a biopsy that produces two further figures: a Gleason score for cell abnormality, and a TNM stage for tumour spread. Ministry of Health guidance classes prostate cancer as low risk at PSA under 10 µg/L, Gleason 3+3=6, and stage T1 or low-volume T2a; intermediate risk at PSA 10 to 20 µg/L or Gleason 7; and high risk at PSA 20+ µg/L, Gleason 8 to 10, or T3 and beyond (Ministry of Health, Guidance on Using Active Surveillance, July 2015).

It is New Zealand's most common cancer in men, with around 4,000 new cases and 700 deaths a year (Te Aho o Te Kahu, read 17 September 2026). PSA testing is far from universal: about 19% of adult men were tested each year from 2015 to 2019, rising to 47% at ages 70 to 79, and about half as common in Māori and Asian men, a third in Pacific men, versus European men (bpac.org.nz, 7 July 2020). A man never tested has nothing to disclose; one with an old, unfollowed reading does.

What is active surveillance, and how does PSA monitoring work?

Active surveillance is a management option, not a decision to leave cancer untreated: it monitors a low-risk tumour closely so treatment starts only if the cancer progresses. Survival runs at around 80%, similar to men who have immediate treatment, which is one reason only 20% to 30% of eligible men choose it; around 30% of those who do eventually exit to treatment, typically within two years (Ministry of Health, Guidance on Using Active Surveillance, July 2015).

Stage	What happens
Entry	PSA under 10 µg/L, Gleason 3+3=6, stage T1 or T2a, life expectancy 10+ years
Early monitoring	Three-monthly PSA, with or without a digital rectal exam
6 to 12 months	Repeat assessment; biopsy and/or MRI considered
Ongoing	PSA every 3 to 12 months, full reassessment every 2 to 4 years
Exit	PSA reaches 10+ µg/L, a repeat biopsy shows Gleason above 6, the stage progresses, or the man chooses treatment

Source: Ministry of Health, Guidance on Using Active Surveillance to Manage Men with Low-risk Prostate Cancer, July 2015.

A kitchen calendar on the wall has four dates circled through the year, with a pair of gumboots waiting by the back door

Active surveillance vs treated: does insurance pay differently for the same diagnosis?

Yes, and on a trauma policy the difference can be the entire payout. A textbook active-surveillance diagnosis, Gleason 3+3=6, PSA under 10, T1, sits on a threshold different insurers write oppositely.

Trauma insurer	Gleason 3+3=6 (the active-surveillance entry grade)	Gleason 5 or below, TNM T1
Fidelity Life (LifeProtect)	Full sum insured	Partial: 25% of the sum insured, up to $50,000
Pinnacle Life (Serious Illness)	Excluded, no benefit	Excluded, no benefit

Source: Fidelity Life, LifeProtect Trauma Cover policy wording, effective 30 April 2025; Pinnacle Life, Serious Illness Definitions.

Under Fidelity Life's LifeProtect Trauma Cover, a Gleason score of 6 or above qualifies prostate cancer for the full sum insured, alongside TNM stage T2 or above, a full prostatectomy, or treatment by radiotherapy or chemotherapy (Fidelity Life LifeProtect Trauma Cover, effective 30 April 2025). Under Pinnacle Life's Serious Illness cover, the same tumour is written oppositely: its definition excludes "prostate tumours equal to or less than a Gleason class 6 or a TNM class T1" (Pinnacle Life, Serious Illness Definitions), an exclusion that stops at Gleason 6; a Gleason 7 or higher diagnosis is not caught by this wording. A man with the textbook active-surveillance profile, Gleason exactly 6, could receive a full trauma payout from one insurer and nothing from another, for the identical diagnosis. QuoteHub's glossary of trauma insurance definitions works through how these thresholds are built for other conditions.

Can you get life insurance after prostate cancer in NZ?

Life insurance underwriting after a prostate cancer diagnosis uses the same figures: Gleason score, PSA and TNM stage, plus how long ago treatment finished and how PSA has behaved since. Insurers typically ask for a urologist summary, recent PSA results and the original pathology report, and assess a man on stable active surveillance differently from one who has completed a prostatectomy or radiotherapy.

Outcomes range from standard rates, through a loading or exclusion, to postponement while PSA stability is confirmed or, in advanced cases, a decline, and vary by insurer and case: since insurers do not share underwriting guidelines, QuoteHub's licensed advisers compare a named panel rather than one insurer. Our wider guide to applying with a pre-existing condition covers the process generally.

Does health insurance cover prostate cancer treatment?

If you already held health insurance before your PSA rose, treatment for prostate cancer is usually a standard claim under the policy's surgical and cancer benefits. Southern Cross, for example, publishes eligibility criteria for reimbursing robotic-assisted laparoscopic prostatectomy: biopsy-proven cancer, a Gleason score of 7 or below, PSA under 10, a BMI under 35, and no sign the cancer has spread (Southern Cross, robotic prostatectomy eligibility criteria, last updated March 2015). A higher-risk cancer or BMI can put the robotic option outside cover, though non-robotic surgery remains available through the public system (Prostate Matters).

Cover bought after a raised PSA or diagnosis differs: a prostate condition already on file when a new health insurance policy starts usually sits inside its pre-existing condition exclusion. ACC has no role either way, since prostate cancer is illness, not injury (ACC, what we cover). Our guide to prostate surgery costs in NZ sets out what TURP and robotic prostatectomy cost.

How does income protection respond to a prostate cancer diagnosis?

Income protection responds to how prostate cancer affects your ability to work, not the diagnosis itself. A man on active surveillance who is asymptomatic and working normally presents a very different claim from one recovering from a prostatectomy or radiotherapy, facing genuine incapacity while the waiting period runs. New applications weigh the same Gleason, PSA and treatment-history questions as life and trauma cover, with outcomes from standard terms to a loading, exclusion or postponement. Our comparison of income protection and trauma cover explains how the two respond to the same diagnosis.

How much do life and trauma cover cost at the ages prostate cancer is usually diagnosed?

Prostate cancer is rare before 50 and grows steadily more common through a man's fifties and sixties, exactly when life and trauma premiums step up sharply with age. These are indicative, standard rates for a non-smoking man in occupation class 1, and monthly premiums price out as follows.

Age, cover	Typical monthly cost
55, $500k life	$170 to $190
60, $500k life	$300 to $375
55, $100k trauma	$190 to $225
60, $100k trauma	$300 to $375

Indicative monthly cost from insurers' published rate cards as at 8 September 2026 (see AIA and Fidelity Life for two insurers' own published rates).

These are standard, indicative rates before any underwriting outcome from a prostate cancer history; a loading or exclusion sits on top of the premium above, and pricing should always be confirmed directly.

What should you do before applying for cover with a prostate cancer history?

Before applying with a prostate cancer history, gather your urologist's latest letter, full PSA history, the pathology report with Gleason and TNM stage, and treatment details. Disclose all of it, including an old elevated PSA that was monitored but never biopsied: in one IFSO case involving a different cancer, an insurer queried a couple's life and trauma cover years later over an undisclosed colonoscopy and a half-forgotten anaemia diagnosis, and the claim was eventually settled at a reduced benefit, since anything on your GP file counts as history you must declare (IFSO, Cancer, non-disclosure).

A licensed adviser can present that file to the insurers on QuoteHub's panel most likely to weigh it favourably, and request an indicative assessment before a formal application.

Frequently Asked Questions

Can I get life insurance while on active surveillance for prostate cancer?

Often, yes. Since active surveillance manages a low-risk tumour, many insurers can offer standard or lightly loaded terms once a urologist confirms PSA and Gleason are stable, though outcomes vary by insurer.

Does a Gleason score of 6 count as cancer for trauma insurance?

It depends entirely on the wording. Fidelity Life's LifeProtect Trauma Cover pays the full sum insured at Gleason 6 or above, while Pinnacle Life's Serious Illness cover excludes prostate tumours at Gleason 6 or below.

Will my existing health insurance still cover treatment?

Usually, if the policy was in force before your PSA rose. Robotic prostatectomy can carry its own eligibility criteria, such as Southern Cross's Gleason, PSA and BMI thresholds, separate from cancer cover.

No. ACC covers accidental injury, and prostate cancer is illness, so diagnosis, treatment and any income loss sit outside ACC entirely.

Talk to a Licensed Adviser

A licensed adviser reviews your PSA history, Gleason score and treatment path, then presents it to the life insurance panel most likely to offer useful terms, with no pressure to buy. Start a free comparison with a QuoteHub adviser to see what is realistically available.

References

Financial advice is provided by Craig Smith Business Services Limited, trading as Smiths Insurance & KiwiSaver, a licensed Financial Advice Provider (FSP712931). QuoteHub is a trading name. General information only; underwriting outcomes vary by insurer and case.

Read the full insurance guides

Compare your cover with a licensed NZ adviser · free, no obligation.

Explore related pages: Life Insurance, Income Protection, Health Insurance, Trauma Insurance, Referral.